Express Pharma

AbbVie and Cugene announce collaboration in autoimmune diseases

Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and regulatory milestones and a licence option exercise payment if AbbVie exercises the option

0 240